# Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

> **NCT02292173** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 17 (actual)

## Conditions studied

- Hepatocellular Cancer
- Liver Cancer

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02292173
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-18
- **Primary completion:** 2018-12-18
- **Final completion:** 2021-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292173, "Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02292173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*